比菲蔻通过调节肠道菌群失调和炎症细胞因子来缓解肠易激综合征。

PURPOSE: Gut microbiota dysbiosis, a core pathophysiology of irritable bowel syndrome (IBS), is closely related to immunological and metabolic functions. Gut microbiota-based therapeutics have been recently explored in several studies. Bifico is a probiotic cocktail widely used in gastrointestinal disorders which relate to the imbalance of gut microbiota. However, the efficacy and potential mechanisms of Bifico treatment in IBS remains incompletely understood. METHODS: Adopting a wrap restraint stress (WRS) -induced IBS mice model. Protective effect of Bifico in IBS mice was examined through abdominal withdrawal reflex (AWR) scores. 16S rDNA, H nuclear magnetic resonance (H-NMR) and western blot assays were performed to analyze alterations of gut microbiota, microbiome metabolites and inflammatory cytokines, respectively. RESULTS: Bifico could decrease intestinal visceral hypersensitivity. Although gut microbiota diversity did not increase, composition of gut microbiota was changed after treatment of Bifico, which were characterized by an increase of Proteobacteria phylum and Actinobacteria phylum, Muribaculum genus, Bifidobacterium genus and a decrease of Parabacteroides genus, Sutterella genus and Lactobacillus genus. Moreover, Bifico elevated the concentration of short-chain fatty acids (SCFAs) and reduced protein levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). From further Spearman's correlation analysis, Bifidobacterium genus were positively correlated with SCFAs including propionate, butyrate, valerate and negatively correlated with IL-6 and TNF-α. CONCLUSION: Bifico could alleviate symptoms of IBS mice through regulation of the gut microbiota, elevating production of SCFAs and reducing the colonic inflammatory response.

目的：肠道微生物失调是肠易激综合征（IBS）的核心病理生理学，与免疫和代谢功能密切相关。最近的几项研究探索了基于肠道微生物的治疗方法。Bifico 是一种广泛用于与肠道微生物失衡相关的胃肠道疾病的益生菌鸡尾酒。然而，Bifico 治疗 IBS 的疗效和潜在机制仍不完全清楚。

方法：采用束缚应激（WRS）诱导的 IBS 小鼠模型。通过腹壁退缩反射（AWR）评分来检测 Bifico 对 IBS 小鼠的保护作用。通过 16S rDNA、H 磁共振（H-NMR）和 Western blot 分析分别分析肠道微生物、微生物代谢物和炎症细胞因子的变化。

结果：Bifico 可降低肠道内脏敏感性。尽管肠道微生物多样性没有增加，但 Bifico 治疗后肠道微生物组成发生了变化，其特征是厚壁菌门和放线菌门、Muribaculum 属、双歧杆菌属增加，拟杆菌属、萨特氏菌属和乳杆菌属减少。此外，Bifico 提高了短链脂肪酸（SCFA）的浓度，并降低了白细胞介素 6（IL-6）和肿瘤坏死因子-α（TNF-α）的蛋白水平。进一步的 Spearman 相关分析表明，双歧杆菌属与包括丙酸盐、丁酸盐、戊酸盐在内的 SCFA 呈正相关，与 IL-6 和 TNF-α呈负相关。

结论：Bifico 通过调节肠道微生物群、提高 SCFA 的产生和减少结肠炎症反应，缓解 IBS 小鼠的症状。